Company intelligence / Profile preview
Anosys, Inc.
Menlo Park, California, United Statesanosys.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Early Phase I trials showed promising safety data in advanced NSCLC and melanoma patients who failed current therapies. A Phase II study was designed to demonstrate initial efficacy but was suspended[1][5].
- Therapeutic areas
- Oncology
- Modalities
- Exosome-based immunotherapies (acellular vesicle therapies)Cancer vaccines using dexosomes/exosomes
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Licensing from Institut National de la Santé et de la Recherche Médicale (INSERM), Gustave-Roussy Institute, Curie Institute in France for patent rights on exosome technology[5].Aventis SA (France)Kirin Brewery Co. Ltd. (Japan)BankInvest Biomedical Venture (Denmark)
Beyond the preview
Go deeper on Anosys, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anosys, Inc..